New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 20, 2012
18:19 EDTMYLMylan announces $500M share repurchase program
Mylan announced that its Board of Directors has approved the repurchase of up to $500M of the company's common stock in the open market or through other methods.
News For MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
16:11 EDTMYLMylan raises FY14 EPS view to $3.54-$3.60, consensus $3.49
Subscribe for More Information
16:08 EDTMYLMylan sees Q4 EPS $1.03-$1.09, consensus $1.00
16:08 EDTMYLMylan reports Q3 EPS $1.16, consensus $1.14
Subscribe for More Information
15:30 EDTMYLNotable companies reporting after market close
Subscribe for More Information
12:50 EDTMYLMylan launches generic Viramune XR
Subscribe for More Information
October 28, 2014
04:58 EDTMYLThe Medicines Co. wins favorable judgement in Angiomax patent litigation
The Medicines Company (MDCO) announced the U.S. District Court for the Northern District of Illinois in The Medicines Company v. Mylan, Inc. entered judgment in favor of The Medicines Company on all issues concerning U.S. Patent No. 7,582,727. Following a June 2014 trial, Judge Amy St. Eve found all of the asserted claims are infringed by Mylanís (MYL) Abbreviated New Drug Application, or ANDA. The same claims were also found to be valid and enforceable. Mylanís ANDA seeks FDA approval to commercially manufacture, use or sell a generic version of The Medicines Companyís Angiomax drug product before the expiration of the í727 patent. The ruling prevents Mylan from obtaining FDA approval of its generic bivalirudin and launching its ANDA product until the earlier of a successful appeal or expiration of the í727 patent in 2028. To appeal successfully, Mylan must overturn the Courtís rulings on each of the asserted claims.
October 27, 2014
18:34 EDTMYLMedicines Co. wins patent suit against Mylan, Bloomberg reports
The Medicines Co. (MDCO) has won a patent suit against Mylan (MYL), Bloomberg reports. A U.S. district court found that Mylan infringed the Medicines Co. patent for its blood-clot-inhibiting drug Angiomax. Shares of Medicines Co. are up 11.5% to $24.76 following the report. Reference Link
12:44 EDTMYLStocks with call strike movement; CELG MYL
Celgene (CELG) April 115 call option implied volatility increased 4% to 30, Mylan (MYL) April 60 call option implied volatility increased 3% to 29 according to IVolatility.
October 23, 2014
08:15 EDTMYLPfizer wins SUTENT patent case In Delaware District Court
Pfizer (PFE) announced today that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering SUTENT capsules. This decision, which is subject to appeal, affirms Pfizerís right to exclusively provide sunitinib malate as SUTENT to patients through the term of the patent, which expires in 2021. Pfizer filed suit in June 2010 after Mylan (MYL) applied to the U.S. Food and Drug Administration to market a generic version of SUTENT prior to the expiration of the patents covering sunitinib malate and its uses. After a four-day trial, the Court agreed that Mylan infringed the valid patents covering SUTENT.
06:22 EDTMYLMylan, Abbott enter into amendment, still see deal closing in 1Q15
Subscribe for More Information
October 22, 2014
11:59 EDTMYLStocks with call strike movement; MYL AMZN
Subscribe for More Information
09:16 EDTMYLAbbott sees Q4 reported sales growth in high single digits
Subscribe for More Information
October 20, 2014
08:04 EDTMYLGerman fund pressured to sell Mylan stake over drug used in executions, FT says
Subscribe for More Information
07:20 EDTMYLInternational Continence Society to hold annual meeting
ICS Annual Meeting 2014 is being held in Rio de Janeiro, Brazil on October 20-24.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use